Ma Liuling, Lai Renkui, Guo Zhehan, Cai Tianjin, Huang Jingyi, Li Jinxin
Department of Arrhythmia, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Cardiovasc Med. 2025 Aug 6;12:1623043. doi: 10.3389/fcvm.2025.1623043. eCollection 2025.
This study investigated efficacy of intraoperative ibutilide administration for cardioversion of persistent atrial fibrillation (AF) during catheter ablation and evaluated predictive factors for postoperative AF recurrence.
A retrospective analysis was conducted involving 111 patients with persistent AF who underwent radiofrequency catheter ablation. Patients who failed to restore sinus rhythm after ablation received intravenous ibutilide (1-2 mg). Patients achieving sinus rhythm post-ibutilide administration were categorized as responders, while non-responders underwent electrical cardioversion. Clinical data were collected, and logistic regression was utilized to identify factors associated with ibutilide response and postoperative AF recurrence.
Sinus rhythm was restored by ibutilide in 73 patients (65.7%). Non-response to ibutilide was independently associated with longer AF duration (OR = 1.82), diabetes ellitus (OR = 2.27), coronary artery disease (OR = 2.56), increased ST2 (OR = 1.08), larger left atrial diameter (LAD) (OR = 1.25), elevated NT-proBNP (OR = 1.01), and higher CHA2DS2-VASc scores (OR = 1.96; all < 0.05). AF recurrence within 3 months post-ablation was independently predicted by intraoperative ibutilide non-response (OR = 5.317), older age (OR = 1.213), diabetes mellitus (OR = 0.14), increased LAD (OR = 1.211), elevated ST2 (OR = 1.139), elevated hs-CRP (OR = 1.276), and higher CHADS-VASc scores (OR = 2.736; all < 0.05).
Intraoperative ibutilide responsiveness significantly predicts postoperative AF recurrence in patients undergoing catheter ablation for persistent AF. Assessing ibutilide response may enhance risk stratification and guide personalized treatment strategies.
本研究探讨术中给予伊布利特对导管消融治疗持续性心房颤动(AF)复律的疗效,并评估术后AF复发的预测因素。
对111例接受射频导管消融的持续性AF患者进行回顾性分析。消融后未能恢复窦性心律的患者接受静脉注射伊布利特(1-2mg)。伊布利特给药后实现窦性心律的患者归类为反应者,而无反应者接受电复律。收集临床数据,并采用逻辑回归分析确定与伊布利特反应及术后AF复发相关的因素。
73例患者(65.7%)经伊布利特恢复窦性心律。对伊布利特无反应与AF持续时间较长(OR=1.82)、糖尿病(OR=2.27)、冠状动脉疾病(OR=2.56)、ST2升高(OR=1.08)、左心房直径(LAD)增大(OR=1.25)、NT-proBNP升高(OR=1.01)以及CHA2DS2-VASc评分较高(OR=1.96;均P<0.05)独立相关。术中伊布利特无反应(OR=5.317)、年龄较大(OR=1.213)、糖尿病(OR=0.14)、LAD增大(OR=1.211)、ST2升高(OR=1.139)、hs-CRP升高(OR=1.276)以及CHADS-VASc评分较高(OR=2.736;均P<0.05)独立预测消融后3个月内AF复发。
术中伊布利特反应性显著预测接受导管消融治疗持续性AF患者的术后AF复发。评估伊布利特反应可能有助于加强风险分层并指导个性化治疗策略。